Header Logo

Srinivas Vourganti

TitleAssistant Professor
InstitutionRush University, Rush Medical College
DepartmentUrology
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6507694491.
    My NIH COMMONS name is SRIVOURGANTI.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ditonno F, Franco A, Manfredi C, Chow AK, Vourganti S, Cherullo EE, Autorino R. Single Port Robotic Pyeloplasty: early single-center experience. Int Braz J Urol. 2023 Nov-Dec; 49(6):757-762. PMID: 37903009.
      Citations:    
    2. Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, Zukowski LB, Vourganti S, Stenzl A, Andriole GL, Antonelli A, De Nunzio C, Autorino R. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. Prostate Cancer Prostatic Dis. 2023 Aug 05. PMID: 37543656.
      Citations:    
    3. Grob G, Rogers D, Pandolfo SD, Vourganti S, Buscarini M, Mehrazin R, Grob BM, Mir MC, Perdon? S, Derweesh IH, Franco A, Cherullo EE, Hemal AK, Autorino R. Oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma: a literature review. Transl Androl Urol. 2023 Aug 31; 12(8):1351-1362. PMID: 37680219.
      Citations:    
    4. Jackson JC, Franco A, Wang D, Autorino R, Vourganti S. Metastasis-directed treatment in kidney cancer. Curr Opin Urol. 2023 09 01; 33(5):375-382. PMID: 37405715.
      Citations:    
    5. Franco A, Pellegrino AA, De Nunzio C, Salkowski M, Jackson JC, Zukowski LB, Checcucci E, Vourganti S, Chow AK, Porpiglia F, Kaouk J, Crivellaro S, Autorino R. Single-Port Robot-Assisted Radical Prostatectomy: Where Do We Stand? Curr Oncol. 2023 04 20; 30(4):4301-4310. PMID: 37185441.
      Citations:    
    6. Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg MR, Tomlins SA. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136. PMID: 35708696.
      Citations:    
    7. Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana-Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais-Bahrami S. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer. 2022 09 15; 128(18):3287-3296. PMID: 35819253.
      Citations:    
    8. Stephenson AJ, Vourganti S. Pro: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. J Urol. 2022 08; 208(2):246-247. PMID: 35549453.
      Citations:    
    9. Setia SA, Smith J, Cendo D, Yoder J, Gorin MA, Allaway MJ, Vourganti S. Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis. BJU Int. 2022 07; 130(1):54-61. PMID: 34491606.
      Citations:    
    10. Setia S, Jackson J, Cendo D, Gorin MA, Allaway M, Vourganti S. Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urol Oncol. 2022 01; 40(1):4.e9-4.e17. PMID: 34688533.
      Citations:    
    11. Chow AK, Vourganti S, Konety BR. Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. Eur Urol. 2021 09; 80(3):386. PMID: 34092438.
      Citations:    
    12. Chow AK, Bhatt R, Cao D, Wahba B, Coogan CL, Vourganti S, Cherullo EE, Bhayani SB, Venkatesh RJ, Figenshau RS. A Case Series of Delayed Proximal Ureteral Strictures After Nephron-Sparing Treatment of Renal Masses. J Endourol Case Rep. 2020; 6(4):544-547. PMID: 33457725.
      Citations:    
    13. Yamada Y, Ukimura O, Kaneko M, Matsugasumi T, Fujihara A, Vourganti S, Marks L, Sidana A, Klotz L, Salomon G, de la Rosette J. Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review. World J Urol. 2021 Mar; 39(3):677-686. PMID: 32728885.
      Citations:    
    14. Vourganti S, Cherullo E. Editorial Comment. J Urol. 2019 11; 202(5):935. PMID: 31343943.
      Citations:    
    15. Setia S, Feng C, Coogan C, Vourganti S, Abern M. Urology Residents' Experience With Simulation: Initial Evaluation of MRI/US Fusion Biopsy Workshop. Urology. 2019 Dec; 134:51-55. PMID: 31542464.
      Citations:    
    16. Gold SA, Shih JH, Rais-Bahrami S, Bloom JB, Vourganti S, Singla N, Baroni RH, Coker MA, Fialkoff J, Noschang J, Roehrborn CG, Turkbey B, Pinto PA. When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion of Prostate Cancer. J Urol. 2019 May; 201(5):943-949. PMID: 30681511.
      Citations:    
    17. Sidana A, Watson MJ, George AK, Rastinehad AR, Vourganti S, Rais-Bahrami S, Muthigi A, Maruf M, Gordetsky JB, Nix JW, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urol Oncol. 2018 Jul; 36(7):341.e1-341.e7. PMID: 29753548.
      Citations:    
    18. Aleksic I, Rais-Bahrami S, Daugherty M, Agarwal PK, Vourganti S, Bratslavsky G. Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urol Ann. 2018 Apr-Jun; 10(2):170-174. PMID: 29719329.
      Citations:    
    19. Vourganti S. Editorial Commentary. Urol Pract. 2018 Mar; 5(2):91. PMID: 37300184.
      Citations:    
    20. Sidelsky S, Setia S, Vourganti S. Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Curr Urol Rep. 2017 Oct 18; 18(12):93. PMID: 29046984.
      Citations:    
    21. Nguyen KA, Syed JS, Luciano R, Shuch B, Vourganti S. Optimizing waiting duration for renal transplants in the setting of renal malignancy: is 2?years too long to wait? Nephrol Dial Transplant. 2017 Oct 01; 32(10):1767-1773. PMID: 28967967.
      Citations:    
    22. Railkar R, Krane LS, Li QQ, Sanford T, Siddiqui MR, Haines D, Vourganti S, Brancato SJ, Choyke PL, Kobayashi H, Agarwal PK. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214. PMID: 28619755.
      Citations:    
    23. Nguyen KA, Vourganti S, Syed JS, Luciano R, Campbell SC, Shuch B. End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes. Urol Oncol. 2017 08; 35(8):529.e1-529.e7. PMID: 28363473.
      Citations:    
    24. Vourganti S, Starkweather N, Wojtowycz A. MR/US Fusion Technology: What Makes It Tick? Curr Urol Rep. 2017 Mar; 18(3):20. PMID: 28233228.
      Citations:    
    25. Daugherty M, Sedaghatpour D, Shapiro O, Vourganti S, Kutikov A, Bratslavsky G. The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urol Oncol. 2017 04; 35(4):153.e15-153.e20. PMID: 28202224.
      Citations:    
    26. Watson MJ, Sidana A, Singer EA, Gupta GN, Rastinehad AR, Vourganti S, Bratslavsky G, Metwalli AR. Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print). Int Urol Nephrol. 2017 Feb; 49(2):267-268. PMID: 27812784.
      Citations:    
    27. Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers. Prostate. 2016 09; 76(13):1135-45. PMID: 27225637.
      Citations:    
    28. Kauffman EC, Lee MJ, Alarcon SV, Lee S, Hoang AN, Walton Diaz A, Chelluri R, Vourganti S, Trepel JB, Pinto PA. Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. J Urol. 2016 Apr; 195(4 Pt 1):1136-42. PMID: 26581128.
      Citations:    
    29. Daugherty M, Blakely S, Shapiro O, Vourganti S, Mollapour M, Bratslavsky G. Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. J Urol. 2016 Apr; 195(4 Pt 1):847-51. PMID: 26555952.
      Citations:    
    30. Manwaring J, Vourganti S, Nikolavsky D, Valente AL, Byler T. Pannus Is the New Prepuce? Penile Cancer in a Buried Phallus. Case Rep Urol. 2015; 2015:403545. PMID: 26446361.
      Citations:    
    31. Martucci VL, Lorenzo ZG, Weintraub M, del Rivero J, Ling A, Merino M, Siddiqui M, Shuch B, Vourganti S, Linehan WM, Agarwal PK, Pacak K. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015 Apr; 33(4):167.e13-20. PMID: 25683602.
      Citations:    
    32. Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015 Mar; 115(3):381-8. PMID: 24447678.
      Citations:    
    33. Rais-Bahrami S, T?rkbey B, Rastinehad AR, Walton-Diaz A, Hoang AN, Siddiqui MM, Stamatakis L, Truong H, Nix JW, Vourganti S, Grant KB, Merino MJ, Choyke PL, Pinto PA. Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol. 2014 Jul-Aug; 20(4):293-8. PMID: 24808435.
      Citations:    
    34. Vourganti S, Donaldson J, Johnson L, Turkbey B, Bratslavsky G, Kotula L. Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Exp Biol Med (Maywood). 2014 Jul; 239(7):805-812. PMID: 24879423.
      Citations:    
    35. Hong CW, Walton-Diaz A, Rais-Bahrami S, Hoang AN, T?rkbey B, Stamatakis L, Xu S, Amalou H, Siddiqui MM, Nix JW, Vourganti S, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol. 2014 May-Jun; 20(3):234-8. PMID: 24509182.
      Citations:    
    36. Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014 Feb 10; 32(5):431-7. PMID: 24378414.
      Citations:    
    37. Truong H, Logan J, Turkbey B, Siddiqui MM, Rais-Bahrami S, Hoang AN, Pusateri C, Shuch B, Walton-Diaz A, Vourganti S, Nix J, Stamatakis L, Harris C, Chua C, Choyke PL, Wood BJ, Pinto PA. MRI characterization of the dynamic effects of 5a-reductase inhibitors on prostate zonal volumes. Can J Urol. 2013 Dec; 20(6):7002-7. PMID: 24331340.
      Citations:    
    38. Shuch B, Hanley JM, Lai JC, Vourganti S, Setodji CM, Dick AW, Chow WH, Saigal CS. Adverse health outcomes associated with surgical management of the small renal mass. J Urol. 2014 Feb; 191(2):301-8. PMID: 24012580.
      Citations:    
    39. Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, Hoang AN, Vourganti S, Truong H, Shuch B, Parnes HL, Turkbey B, Choyke PL, Wood BJ, Simon RM, Pinto PA. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013 Sep 15; 119(18):3359-66. PMID: 23821585.
      Citations:    
    40. Walton Diaz A, Hoang AN, Turkbey B, Hong CW, Truong H, Sterling T, Rais-Bahrami S, Siddiqui MM, Stamatakis L, Vourganti S, Nix J, Logan J, Harris C, Weintraub M, Chua C, Merino MJ, Choyke P, Wood BJ, Pinto PA. Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol. 2013 Dec; 190(6):2020-2025. PMID: 23792130.
      Citations:    
    41. Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, Hoang AN, Walton-Diaz A, Shuch B, Weintraub M, Kruecker J, Amalou H, Turkbey B, Merino MJ, Choyke PL, Wood BJ, Pinto PA. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013 Nov; 64(5):713-719. PMID: 23787357.
      Citations:    
    42. Rais-Bahrami S, Siddiqui MM, Turkbey B, Stamatakis L, Logan J, Hoang AN, Walton-Diaz A, Vourganti S, Truong H, Kruecker J, Merino MJ, Wood BJ, Choyke PL, Pinto PA. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol. 2013 Nov; 190(5):1721-1727. PMID: 23727310.
      Citations:    
    43. Shuch B, Hanley J, Lai J, Vourganti S, Kim SP, Setodji CM, Dick AW, Chow WH, Saigal C. Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer. 2013 Aug 15; 119(16):2981-9. PMID: 23674264.
      Citations:    
    44. Vourganti S, Harbin A, Singer EA, Shuch B, Metwalli AR, Agarwal PK. Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? - Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database. J Cancer. 2013; 4(4):336-42. PMID: 23678370.
      Citations:    
    45. Kauffman EC, Robinson BD, Downes M, Marcinkiewicz K, Vourganti S, Scherr DS, Gudas LJ, Mongan NP. Estrogen receptor-? expression and pharmacological targeting in bladder cancer. Oncol Rep. 2013 Jul; 30(1):131-8. PMID: 23612777.
      Citations:    
    46. Shuch B, Hofmann JN, Merino MJ, Nix JW, Vourganti S, Linehan WM, Schwartz K, Ruterbusch JJ, Colt JS, Purdue MP, Chow WH. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urol Oncol. 2014 Jan; 32(1):23.e9-13. PMID: 23453468.
      Citations:    
    47. Yerram NK, Volkin D, Turkbey B, Nix J, Hoang AN, Vourganti S, Gupta GN, Linehan WM, Choyke PL, Wood BJ, Pinto PA. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int. 2012 Dec; 110(11 Pt B):E783-8. PMID: 23130821.
      Citations:    
    48. Vourganti S, Rastinehad A, Yerram N, Nix J, Volkin D, Hoang A, Turkbey B, Gupta GN, Kruecker J, Linehan WM, Choyke PL, Wood BJ, Pinto PA. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012 Dec; 188(6):2152-2157. PMID: 23083875.
      Citations:    
    49. Singer EA, Vourganti S, Lin KY, Gupta GN, Pinto PA, Rastinehad AR, Linehan WM, Bratslavsky G. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol. 2012 Dec; 188(6):2084-8. PMID: 23083858.
      Citations:    
    50. Turkbey B, Huang R, Vourganti S, Trivedi H, Bernardo M, Yan P, Benjamin C, Pinto PA, Choyke PL. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU Int. 2012 Dec; 110(11):1642-7. PMID: 22973825.
      Citations:    
    51. Hoang AN, Volkin D, Yerram NK, Vourganti S, Nix J, Linehan WM, Wood B, Pinto PA. Image guidance in the focal treatment of prostate cancer. Curr Opin Urol. 2012 Jul; 22(4):328-35. PMID: 22647649.
      Citations:    
    52. Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R. Targeting the mTOR pathway in Chromophobe Kidney Cancer. J Cancer. 2012; 3:152-7. PMID: 22481981.
      Citations:    
    53. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012 Jun; 109(11):1600-6. PMID: 22221668.
      Citations:    
    54. Vourganti S, Shuch B, Bratslavsky G. Surgical management of large renal tumors. Expert Rev Anticancer Ther. 2011 Dec; 11(12):1889-900. PMID: 22117156.
      Citations:    
    55. Stovsky M, Ponsky L, Vourganti S, Stuhldreher P, Siroky MB, Kipnis V, Fedotoff O, Mikheeva L, Zaslavsky B, Chait A, Jones JS. Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples. Urology. 2011 Sep; 78(3):601-5. PMID: 21783231.
      Citations:    
    56. Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, Trepel JB, Prodromou C, Pearl LH, Neckers L. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell. 2011 Mar 18; 41(6):672-81. PMID: 21419342.
      Citations:    
    57. Vricella GJ, Ross JH, Vourganti S, Cherullo EE. Laparoendoscopic single-site nephrectomy: initial clinical experience in children. J Endourol. 2010 Dec; 24(12):1957-61. PMID: 20846003.
      Citations:    
    58. Ponsky LE, Steinway ML, Lengu IJ, Hartke DM, Vourganti S, Cherullo EE. A Pfannenstiel single-site nephrectomy and nephroureterectomy: a practical application of laparoendoscopic single-site surgery. Urology. 2009 Sep; 74(3):482-5. PMID: 19646739.
      Citations:    
    59. Vourganti S, Agarwal PK, Bodner DR, Dogra VS. Ultrasonographic evaluation of renal infections. Radiol Clin North Am. 2006 Nov; 44(6):763-75. PMID: 17147985.
      Citations:    
    60. Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. 2004 Oct 06; 96(19):1447-57. PMID: 15467034.
      Citations:    
    61. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, Caligiuri MA. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 01; 63(5):965-71. PMID: 12615710.
      Citations:    
    62. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 2002 Oct 01; 100(7):2341-8. PMID: 12239141.
      Citations:    
    63. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest. 2001 Sep; 108(6):887-94. PMID: 11560958.
      Citations:    
    Vourganti's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (228)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _